ID: ALA3797933

Max Phase: Preclinical

Molecular Formula: C18H19N7O

Molecular Weight: 349.40

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  Nc1nc2cc(-c3nn(CC4CCCC4)c4ncnc(N)c34)ccc2o1

Standard InChI:  InChI=1S/C18H19N7O/c19-16-14-15(11-5-6-13-12(7-11)23-18(20)26-13)24-25(17(14)22-9-21-16)8-10-3-1-2-4-10/h5-7,9-10H,1-4,8H2,(H2,20,23)(H2,19,21,22)

Standard InChI Key:  GUFVTKTWKYLOQP-UHFFFAOYSA-N

Associated Targets(Human)

MTOR Tclin Serine/threonine-protein kinase mTOR (13850 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PIK3CA Tclin PI3-kinase p110-alpha subunit (12269 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PIK3CB Tchem PI3-kinase p110-beta subunit (4044 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PIK3CG Tclin PI3-kinase p110-gamma subunit (5411 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PIK3CD Tclin PI3-kinase p110-delta subunit (6699 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
DDR1 Tchem Epithelial discoidin domain-containing receptor 1 (1050 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PRKDC Tchem DNA-dependent protein kinase (1929 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
MCF7 (126967 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
MDA-MB-231 (73002 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
U-87 MG (3946 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
T98 (33 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 349.40Molecular Weight (Monoisotopic): 349.1651AlogP: 2.99#Rotatable Bonds: 3
Polar Surface Area: 121.67Molecular Species: NEUTRALHBA: 8HBD: 2
#RO5 Violations: 0HBA (Lipinski): 8HBD (Lipinski): 4#RO5 Violations (Lipinski): 0
CX Acidic pKa: 13.86CX Basic pKa: 3.77CX LogP: 2.53CX LogD: 2.53
Aromatic Rings: 4Heavy Atoms: 26QED Weighted: 0.58Np Likeness Score: -0.93

References

1. Fraser C, Carragher NO, Unciti-Broceta A.  (2016)  eCF309: a potent, selective and cell-permeable mTOR inhibitor,  (3): [10.1039/C5MD00493D]
2. Valero T, Baillache DJ, Fraser C, Myers SH, Unciti-Broceta A..  (2020)  Pyrazolopyrimide library screening in glioma cells discovers highly potent antiproliferative leads that target the PI3K/mTOR pathway.,  28  (1): [PMID:31787462] [10.1016/j.bmc.2019.115215]

Source